Results 81 to 90 of about 5,420 (200)

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

BMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee, Joshua P. Havens, Harlan R. Sayles, Jennifer L. O’Neill, Anthony T. Podany, Susan Swindells, Kimberly K. Scarsi, Sara H. Bares   +7 more
doaj   +1 more source

Impact on weight of a Doravirine switch in people living with HIV

HIV Medicine, Volume 27, Issue 1, Page 136-145, January 2026.
Abstract Background and Objective Doravirine is among the first‐line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti‐integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we
Nina Garofoli, Philippe Flandre, Jean‐Paul Vincensini, Quentin Richier, Priscille Couture, Karine Lacombe, Gilles Pialoux, Jean‐Luc Meynard   +7 more
wiley   +1 more source

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment in HIV/HBV-coinfected patients.

Journal of Acquired Immune Deficiency Syndromes, 2020
BACKGROUND The efficacy and safety of switching from tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has not been widely investigated in HIV ...
Yu-Shan Huang, Chien-Yu Cheng, Bo-Huang Liou, P. Lu, Shu-Hsing Cheng, Yuan-Ti Lee, Chun-Eng Liu, Hsin-Yun Sun, Chia-Jui Yang, Hung-Jen Tang, Shi-ping Lin, M. Ho, Sung-Hsi Huang, H. Tsai, Chen-Hsiang Lee, C. Hung   +15 more
semanticscholar   +1 more source

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

Retrovirology, 2018
Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance.
Maureen Oliveira, Ruxandra-Ilinca Ibanescu, Kaitlin Anstett, T. Mesplède, J. Routy, M. Robbins, B. Brenner, Mario Jean-Guy Louise Marc-André Pierre Alexandra Serge Legault Baril Charest Charron Côté de Pokomandy Du, Mario Legault, J. Baril, L. Charest, M. Charron, P. Cote, A. de Pokomandy, S. Dufresne, C. Fortin, Jason Friedman, N. Gilmore, E. Huchet, M. Klein, Louise Labreque, R. Lalonde, R. Leblanc, B. Lessard, C. Milne, M. Munoz, M. Potter, D. Rouleau, J. Routy, J. Szabo, Réjean Thomas, C. Tremblay, B. Trottier, S. Vézina   +33 more
semanticscholar   +1 more source

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Journal of the International AIDS Society, Volume 28, Issue 12, December 2025.
Abstract Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL] <50 copies/mI individuals. In clinical trials, CAB+RPV LA was non‐inferior to oral antiretroviral therapy (ART) regimens in virologically suppressed individuals ...
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
wiley   +1 more source

Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.

International Journal of Infectious Diseases, 2019
OBJECTIVE To evaluate the evolution of weight and lipid profiles before and after switch to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) among virally suppressed HIV-positive patients.
Po-Hsien Kuo, Hsin-Yun Sun, Y. Chuang, Pei-Ying Wu, Wen-Chun Liu, C. Hung   +5 more
semanticscholar   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study

Infectious Diseases and Therapy, 2019
Introduction Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy (ART), and a need exists to compare their clinical effectiveness, as defined by virologic failure ...
Anthony M. Mills, Laurence Brunet, Jennifer S. Fusco, Michael B. Wohlfeiler, Cindy P. Garris, Alan K. Oglesby, Joseph M. Mrus, Philip C. Lackey, Gregory P. Fusco   +8 more
doaj   +1 more source

HIV–1 resistance to dolutegravir: update and new insights

Journal of Virus Eradication, 2015
Integrase strand transfer inhibitors (INSTIs) are the latest class of potent anti-HIV drugs. Currently, three INSTIs have been approved by the US Food and Drug Administration: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG).
Mark A. Wainberg, Ying-Shan Han
doaj   +1 more source